initi outperform target price
azedra relistor provid base valuat believ progen
royalti futur mileston relistor revenu azedra
support core busi npv rational
azedra first fda-approv agent treat ultra-orphan
diseas physician year experi non-approv
version azedra relistor gener steadi growth
past three year becom three-play market
prostat cancer opportun offer interest option
commerci uptak azedra begin unfold investor focu expect
turn upsid opportun prostat cancer psma-target diagnost
therapeut approach novarti recent acquisit endocyt
support pharma interest attract valuat space progen
current develop diagnost therapeut
modal develop respect
multipl upsid driver long timelin and/or competit
market await azedra label expans opportun like three
four year away await regulatori clariti pyl data like
avail earli data influenc uptak year
behind competit limit data avail date initi data
key though littl valu current bake
valuat initi outperform rate price
blend dcf valuat weight asset valu accord po
well premium downsid risk thesi includ clinic trial
competitor
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
progen engag develop product target
treat cancer pipelin includ agent target cancer
agent prostat cancer imag analysi tool
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky scenario reflect success launch pyl
posit data would support
 weight increas
grey sky scenario assum failur prostat cancer
clinic trial modest penetr azedra pheo/para
addit valu assign azedra lcm opportun
 close
initi coverag progen oncology-focus compani
outperform rate target price relistor azedra provid defin base
valuat view suggest downsid risk share limit
current level howev visibl timelin potenti upsid driver limit
despit multipl possibl long-term sourc option includ azedra geograph
develop prostat cancer therapeut enter develop
azedra first fda-approv agent treatment ultra-rar orphan diseas
pheochromocytoma paraganglioma pheo/para see
annual opportun longer term believ opportun could worth
present await clariti regulatori path forward support expand
label azedra main competitor lutathera novarti studi
similar indic could potenti better efficacy/safeti profil
psma prostate-specif membran antigen diagnost therapeut platform
offer solid option progen view howev competit landscap
crowd diagnost asset pyl dose first patient trial
condor new ppv-like primari endpoint use correct local
rate though regulatori preced endpoint
fundament similar two endpoint thu continu see solid
probabl success sinc pyl abl achiev statist signific posit
predict valu ppv trial osprey
prostat cancer therapeut progen soon-to-begin provid
initi understand efficaci safeti product repeat-dos set
encourag data small single-cent investig
initi trial iit germani interpret limit trial size single-dos
exposur meanwhil progen compet psma radiotherapeut market share
novartis/endocyt compound three- four-year
lead market
progen receiv tier royalti sale mileston bausch health
opioid-induc constip agent relistor relistor project achiev
annual sale recent ip extens suggest product may life
earli balanc sheet end
support capit need
credit suiss biotech short-term outlook expect share price
next month primarili driven azedra commerci uptak
execut clinic develop timelin pyl
driven clinic develop progen psma program psma imag
agent pyl data expect earli psma therapeut agent
interim data potenti end cash progen fund complet
registr trial pyl gener interim data
credit suiss biotech outlook see nearbi base valu
compani think progen prospect acquisit target longer term
natur primarili base upsid case develop prostat
cancer agent expect sentiment would build proof-of-concept
establish and/or pyl success complet registr trial
azedra approv agent pheo/para
broad adopt market small special
sale forc allow effect reach
center us treat major patient
address popul might small drive upsid
includ high rate cytopenia risk kidney
failur
function
significantli limit physician util limit commerci
chanc
believ azedra use support fact nation comprehens cancer network nccn recent
ad treatment guidelin dont expect signific reimburs hurdl azedra small diseas
prevalence/incid pheo/para like lifetim dose ceil limit initi commerci opportun
ii psma imag agent pyl prostat cancer
pyl shown abl character sever
diseas result may posit influenc physician
treatment decis result support pyl use across
stage diseas pyl becom frequent use
workup process us biochem recurr
progen use novel primari endpoint support potenti
approv unclear much read result
previou trial differ primari endpoint psma
imag agent reserv advanc patient
potenti metastas significantli narrow address
market competit threat also pressur commerci
see high unmet need addit prostat cancer diagnost believ psma diagnost well-posit fill void
progen pyl could becom first approv psma diagnost howev multipl competit approach develop
may limit adopt includ physician alreadi experi use off-label
demonstr clinic meaning efficaci
well-toler grant earlier develop compar
psma-target therapi abl demonstr non-
inferior could gener meaning sale expect
larg market
iodin therapeut radionuclid may promis
radionuclid develop high rate xerostomia
observ iit could problemat pgnx trial
iit sampl size small efficaci data cautious
believ iit small draw broad conclus await data understand product profil fit within
treatment paradigm advanc prostat cancer market abl support multipl billion-dollar therapeut agent believ
abl captur materi revenu abl produc compar improv product profil lead competitor
valuat blend dcf valuat assum discount rate given early-stag commerci
compani weight valu primari asset accord po assign pipelin
downsid risk clinic trial delays/failur posit clinic develop competitor financ commerci
data studi
azedra first market malignant/metastat
azedra radiolabel metaiodobenzylguanidin iobenguan
mibg compound fda-approv agent treat patient unresect
expect broad adopt azedra label indic major patient
treat center us physician alreadi experi
mibg therapeut option gener believ azedra favor clinic
azedra address patient popul pheo/para incid
basi model assum us peak sale approach pheo/para though
assum ramp moder consensu
label expans opportun indicationsinclud neuroblastoma gi
carcinoid tumorsoff potenti increment revenu upsid sever hundr
million dollar annual azedra visibl clinic develop timelin
effort improv long-term see possibl long-term competit
variou neuroendocrin tumor set incl pheo/para radiotherapeut
azedra approv juli treatment pheochromocytoma
paraganglioma pheo/para rare neuroendocrin tumor pheo/para indistinguish
one anoth cellular level differ term biolog locat pheo
locat adren medulla para locat ganglia along sympathet
parasympathet chain combin incid rate pheo/para around two
symptom pheo para non-specif includ anxieti sweat sever
headach elev blood pressur could interpret mani
differ maladi metabolit catecholamin discov patient
urin plasma work-up pheo/para conduct approxim
patient malign diseas ayala-ramirez et al five
year surviv malignant/metastat patient inaki et al
death caus tumor progress addit caus
cardiovascular complic owe uncontrol secret catecholamin
clinician gener adopt watch wait approach patient first diagnos
tumor grow widespread patient receiv
aggress treatment gold standard resect potenti
cur relaps post-surgeri inoper tumor receiv
pharmacolog therapi current nccn guidelin recommend radiat front-
line pharmacolog agent follow azedra patient mibg
posit chemotherapi figur treatment paradigm
diagnos pheo/para patient
mibg- progress azedra
azedra mechan action clinic profil
azedra radiolabel metaiodobenzylguanidin iobenguan
mibg compound drug structur similar neurotransmitt norepinephrin
preferenti taken neuron exist tumor
cell insid cell produc anti-cancer effect tumor necrosi cell death
high-energi beta-ray emiss
azedra approv special protocol agreement fda base result
registr trial patient studi receiv two dose azedra
mbq/dose follow treatment patient achiev reduct
hypertens medic least six month addit achiev partial
respons stabl diseas within month figur detail
lower bound
upper bound
partial respons stabl
durabl reduct baselin antihypertens medic use month
least first
number patient
respond
durat respons
greater equal
doctor expert perspect azedra launch
survey multipl doctor get perspect commerci launch
conclus includ follow
azedra use consult expect azedra wide adopt
cytopen ae profil lack surviv claim pivot trial physician
note comfort azedra moa use non-
fda-approv metaiodobenzylguanidin mibg year
dearth
patient treat hand center accord dana-farb
cancer blood disord center dana-farb websit approxim
hospit alreadi access mibg believ center treat
larg proport target patient addit patient exist peripheri
on-demand dose seemingli challeng surmount progen
partner centr probe develop commerci manufactur
deliv person azedra dose made-to-ord therapeut pose
logist challeng consult believ wont major issu on-demand
servic radionuclid foreign concept bayer healthcar deliv
radiotherapeut xofigo prostat cancer patient bone metastas
method manag state current capac abl satisfi project
demand next one two year
reimbursement/access concern manag doctor
interview express concern regard reimburs complex
potenti high cost azedra progen on-going support program azedra
servic connect help facilit reimburs process physician
occup clinic
 chief larg academ center
center focus gi
medic doctor co-director
neuroendocrin tumor program
ye clinic trial
ye intend switch azedra
ye intend switch azedra
consid os data
well-toler mani
patient requir intervent
due cytopenia need
respons rate
activ
overal safeti profil fine
biggest issu would
reimburs
beliv efficaci good
believ could
potenti use ahead
resect case involv
skull spine chest
abdomen
cost/reimburs
identifi patient
understand appropri
patient fit
reimburs mibg
cover access challeng
believ take year build
awar azedra
public outsid major
center due rariti
suggest
complic center
would continu util mibg
suggest physician educ
would necessari
medic commun manag
pheo/para patient alreadi
familiar enough diseas
consid mani malignant/metastat patient would left post-resect possibl radiat mibg posit
launch prepar potenti azedra life-cycl manag
progen abl launch azedra modest sale forc current
commerci team consist ten field-bas personnel five in-hous rep
believ adequ target center treat major
patient us manag comment physician interest azedra appear
high cite sinc approv five non-target center reach look access
drug
longer term progen plan expand azedra use neuroendocrin tumor
mibg avid accord progen initi discuss fda suggest
agenc amen mibg-avid basket trial potenti indic compani may
includ basket trial neuroblastoma merkel cell figur
comprehens list potenti indic time manag believ
enrol patient per indic may adequ potenti support regulatori
approv expect updat
study/studi
potenti
assum similar price point one dose pheo/para patient receiv dose except neuroblastoma given pediatr diseas
assum lutathera address patient popul overlap azedra given lutathera potenti stronger clinic profil lower price point assign
market penetr mibg avid patient
assum lutathera address patient popul overlap azedra given lutathera potenti stronger clinic profil lower price point assign
market penetr mibg avid patient
novarti lutathera may challeng azedra current futur
lutathera approv fda jan treat somatostatin
multipl iit stand jeopard azedra peak market potenti lutathera
explor indic includ pheo/para may
noteworthi iit basket trial irrespect tumor type patient
enrol base somatostatin receptor avid least one tumor site
reliabl evalu ct mri initi primari complet
efficaci lutathera iit larg depend degre somatostatin
receptor express tumor cell within differ indic efficaci
establish see potenti materi adopt owe toler safeti
profil substanti lower rate sever cytopenia one studi posit
demonstr dotat abil taken pheo/para tumor cell chang et
al definit whether higher avid mibg pheo/para
neuroendocrin tumor note tumor may avid mibg
somatostatin therebi potenti set scenario patient could receiv
altern treatment fail
patient isol post-administr key competit factor novarti
posit lutathera outpati radiopharmaceut azedra requir
overnight stay hospit owe reduc hospit cost patient
conveni could posit lutathera azedra manag suggest
patient fact isol receiv lutathera isol rate averag
length stay lutathera remain seen would like highlight
lutathera deliv mic radioact less azedra per visit
lutathera lower price point lutathera price dose
full cours price tag compar azedra recommend cours dose
ultim forecast us azedra revenu approach pheo/para
support valuat potenti lt upsid label expans
model ex-u revenu manag highlight sever differ
eu regulatori strategi contempl includ pursu name patient sale
run registr trial clariti strategi ex-u partner
announc sometim
price manag guid toward base
amount drug given clinic trial azedra one
expens oncolog therapeut market reflect extrem nich
market serv
doses/pati studi total patient treat
receiv one dose presum limit receiv two dose
number malignant/metast
emerg psma-target modal prostat cancer diagnost
therapeut space provid opportun progen accord doctor
interview progen build capabl
believ progen late-stag imag agent pyl pois early-mov
among crowd landscap psmatarget diagnost develop
data suggest capabl identifi distant metastas prostat cancer
patient fail initi therapi
confirmatori trial pyl recent initi expect readout earli
progen develop all-encompass platform address prostat cancer
compris psma-target imag agent psma-target therapeut
glycoprotein normal exist human prostat epithelium express nearli
higher prostat cancer cell meller furthermor express
grow commensur rise patient prostate-specif antigen blood
level well tumor stage grade
progen diagnost candid pyl fluorin psma-target pet
imag agent detect recurr and/or metastat prostat cancer pyl
compos small molecul urea-bas radiotrac label fluorin
radioisotop pyl administ small molecul bind tumor cell
express psma subsequ attach fluorin isotop begin decay result
positron emit set reaction detect pet
see high unmet need novel prostat cancer diagnost approxim
peopl us diagnos prostat cancer year
schwarzenboeck et al biochem recurr figur
overview prostat cancer diagnosi roadmap nation comprehens cancer
network nccn guidelin recommend multipl diagnostic/imag option
patient popul howev literatur expert suggest need novel
diagnost agent better inform treatment decis
biopsi
 activ surveil
mri cholin
fluciclovin pet/ct pet/mri
decis may util one
combin modal depend
monitor cours diseas
expect interven potenti
cur therapi cancer progress
charl martineau pm univers toronto specif probabl
test result neg
diseas present
sensit probabl
test result posit
diseas present
ppv probabl
diseas present
test posit
percentag
subject one-to-on
correspond
local least one
lesion identifi imag
agent composit truth
compani report pyl osprey result multi-cent open-
label studi enrol patient across two cohort cohort consist high-risk
prostat cancer patient plan radic prostatectomi cohort consist
prostat cancer patient local recurr metastat diseas cohort pyl
achiev specif lower bound ci
pre-specifi posit predict valu ppv measur cohort
show statist signific ci howev result mix
sensit endpoint lower bound ci slightli lower
target figur detail
ultim believ result partial de-risk recent commenc trial
condor fda agre progen propos use new clinic endpoint call
correct local rate manag frame endpoint ppv-like
sinc formula calcul ppv differ ppv
latter take account number subject diseas
former design focu lesion detect anoth key differ
enrol patient would test neg addit lesion
standard convent imag view success condor would clinic
meaning result pyl would demonstr util biochem recurr patient
unexplain rise psa despit neg find use convent imag
knowledg axumin imag agent approv ppv
primari endpoint given similar ppv comfort
po would similar situat clinic endpoint preced
moreov threshold assumpt lower bound ci success
figur result osprey trial
multi-cent multi-read open-label efficacy/safeti studi
multi-cent multi-read open-label efficacy/safeti studi
dcfpyl pet/ct imag patient suspect recurr
dcfpyl pet/ct imag patient prostat cancer
prostat cancer neg equivoc find
center
singl dose inject pyl follow whole bodi
singl dose inject pyl mci follow whole bodi
pet/ct scan within hour dose
histolog confirm adenocarcinoma prostat
high-risk prostat cancer patient plan radic prostatectomi
lymphadenectomi
prostat cancer patient local recurr metastat diseas
will undergo biopsi
pet/ct scan within hour dose
neg equivoc find prostat cancer convent
imag perform part standard care workup within day
prior day
cohort patient prior androgen depriv therapi
antiandrogen gnrh lhrh agonist antagonist prostat
investig neoadjuv agent intervent
on-going treatment system therapi
treatment past month day
sensit specif pyl pet/ct imag detect
metastat prostat cancer within pelvic lymph node rel
histopatholog cohort
posit neg predict valu ppv npv pyl
imag predict prostat cancer within prostat gland
lymph node cohort
ppv pyl imag predict prostat cancer within site local
recurr metastat lesion cohort
sensit pyl detect prostat cancer within site metastasi
local recurr rel histopatholog cohort
percentag subject chang intend prostat cancer
treatment plan due pyl pet/ct imag result threshold
lower bound ci success criteria
specif lower bound ci
sensit lower bound ci
ppv npv respect
trial protocol requir lower limit two-sid ci specif exceed sensit exceed
approxim patient diagnos prostat cancer annual us
nih/nci seer biochem recurr rate
patient opportun approxim opportun assum
price current center us regularli use psma diagnost label
would expect number adopt meaning increas psma diagnost
therapeut landscap evolv approv product come market evan et
commerci launch earth diagnost axumin radiolabel small molecul
fluciclovin diagnost support potenti market opportun pyl axumin
approv late februari axumin avail center
across us gener revenu month end march
accord syncona invest compani own earth
uniqu patient receiv axumin date axumin cost suggest
progen project price point competit current option especi
abl demonstr high ppv valu
progen approxim two-year lead psma imag agent
develop multipl competit approach develop see figur
list variou prostat cancer diagnost progen closest competitor
pipelin target agent telix pharmaceut fair amount
physician alreadi familiar non-approv agent
introduc medic commun ahead psma tracer
moreov label psma-target imag agent util companion
develop
axumin assess histopatholog
biopsi scan ppv pet/ct
tumor prostate/prost bed record
ppv extraprostat tumor
ppv
ppv sampl lesion
studi four independ studi
cholin pet/ct scan posit
patient two fals posit
prostat fossa biopsi show cancer
primari high-risk
newly-diagnos
risk pelvic node
cohort compris treatment nave
patient schedul prostatectomi
cohort compris metastat
prostat cancer patient repres
demonstr least one unequivoc
psma-avid focu compar
cohort patient similar number
metastas identifi
ctm bone scintigraphi bs fdg pet
follow imag
ct bs fdg
fdg
patient post
patient mpc
conduct univers
data demonstr
cohort pyl osprey
demonstr
compar
detect
patient
real-world util due
inaccuraci compar newer
singl center studi
uk extra cohort primari
complet date dec
still list imaginab websit
in-licens cancer
aaa also develop
psma target agent serv
companion diagnost
psma therapeut develop
see advantag disadvantag pyl time
doctor interview gener see two agent compar
literatur suggest pyl may potenti better imag agent compar
target compar iit studi show pet/ct abl identifi
suspici lesion detect biochem recurr
patient pyl also abl identifi addit suspici lesion probabl
metastas patient posit scan dietlein
howev logistically/administr cumbersom see figur
comparison
current use practic
major avail data psma pet
imag obtain agent
label
gener kept on-site
allow deliveri distant center
lower positron energi suggest
cyclotron produc high product
yield use clinic
scan prefer perform hous
current use practic
major avail data psma pet
imag obtain agent
label
gener kept on-site
allow deliveri distant center
scan prefer perform hous
requir cyclotron decay smaller
hospit academ center gener
support necessari infrastructur
oper cyclotron
lower positron energi suggest
cyclotron produc high product
yield use clinic
requir cyclotron decay smaller
hospit academ center gener
support necessari infrastructur
oper cyclotron
giesel journal nuclear medicin credit suiss estim
although regulatori preced threshold pyl believ
there good probabl progen achiev primari endpoint given
fundament similar ppv posit data shown osprey
trial ppv owe lack visibl ex-u expans model
market opportun outsid us model pyl reach us peak
sale potenti upsid differenti data rel ga approach clariti
ex-u strategi potenti pyl use up-front set low-high risk
patient prior cur therapi
images/pati
biochem recurr market use psma imag agent
pyl market share within psma market given current use
imag agent across larg academ center us
util companion diagnost therapeut agent clinic
develop logist friendli manufacturing/compound
patietn receiv imag mri/ct/pet
market use psma imag brand
posit outlook psma-target
progen develop small molecul psma-target therapeut
treatment metastat castration-resist prostat cancer mcrpc patient
psma avid approxim prostat cancer case advanc mcrpc see
figur treatment paradigm patient fall categori
significantli lower surviv compar patient without metastas addit
novel therapeut need treat popul novarti recent acquisit
endocyt psma-target therapeut total deal valu valid
random placebo-control trial expect commenc earli
trial plan enrol metastat castrat resist prostat cancer patient
primari endpoint trial prostat specif antigen respons rate accord
prostat cancer clinic trial work group criteria secondari endpoint
includ progression-fre surviv overal surviv figur detail
believ manag elect explor repeat lower dose util iit
offer cleaner/manag safeti profil though creat uncertainti
around expect efficaci profil expect potenti interim result studi
late earli
multi-cent random control trial evalu efficaci
safeti combin enzalutamid
psma-avid chemotherapi nave progress abirateron
manag state lower dose iit dose cycl
prostat specif antigen respons rate accord prostat
cancer clinic trial work group criteria defin
confirm greater declin baselin
enzalutamid compar enzalutamid alon
radiograph respons base recist
previous complet investig initi trial iit germani help frame
expect trial studi efficaci safeti evalu
patient receiv one cycl detail figur though efficaci respons
appear encourag safeti data show high amount radiat
reach salivari gland iodin histori signific salivari gland uptak
clinic trial differ indic drawn concern potenti
perman salivari gland damag one case mucos iit given
dose cycl safeti profil point focu
addit on-going dose-find investig initi trial memori
sloan-kett trial start januari unclear result
studi publish
prostat cancer treatment landscap evolv sever psma agent
develop see figur detail three compon may differenti
one compound anoth radionuclid cytotox agent linker
ligand pepdidomimet mab
develop progen explor patient pre-chemo
administ patient post-chemo although exact ramif
differ unclear addit use lutetium use
iodin key differ two radionuclid iodin releas medium
energi gamma radiat decay lutetium releas low energi gamma
radiat gamma radiat primari culprit caus damag surround heathi
tissu ultim addit clinic data need compar two agent
novartis/endocyt current
single-arm single-cent prospect trial evalu efficaci
safeti qol
protocol studi evalu efficaci safeti qol
one cycl mean activ gbq rang gbq
valu decreas men treat
reduct bone pain assess patient
decreas pain sever result remain two patient
median time progress day rang
level normal grade
platelet level normal grade
erythrocyt normal patient lower
valu prior therapi
transient slight moder dri mouth one case
cycl week interv mean administ radioact
gbq/cycl rang
receiv one cycl
receiv cycl two three four respect
previou line therapi
least one line previou chemotherapi
prior abirateron enzalutamid
valu decreas ci
point improv pain score
safeti drug-rel
interim analysi addit patient present
data cut-off
valu decreas ci
figur competit landscap psma-target agent
deliv radiat
therapi direct
site tumor
psma mcrpc
progress
deliv radiat
therapi direct
site tumor
random trial patient
progress psma
combin
target psma
deliv radiat
therapi direct
site tumor
dose-escal
patient psma
toler radiat
safeti qol
mcrpc patient
iit compassion use set mcrpc
patient cycl
valu decreas
men bone pain
show complet moder reduct pain
transient slight moder dri
mouth case mucos
mcrpc patient line prior
chemotherapi prior
cycl six weekli
reduct least baselin
patient patient
patient
median month median os
mcrpc patient cohort fraction
dose monotherapi cohort
cohort respons rate report
cohort respons rate report
data gener singl site
iit germani compassion
util combin
enzalutamid
os rpf analysi
dose gbq cycl
maximum
util combin
best supportive/ best soc
defin local investig
dose limit toxic
endocyt expect
suspend trial
acquir advanc
induc express
immun respons
combo ino-
men
psma prostat
cell t-
dose-escal
analysi show
monotherapi increas cell respons
peripher blood subject
patient specif cell respons
experienc slow rise
increas doubl time favor
grade sae patient grade
report grade
patient develop ada high
titer high due
ada patient high ada titer clear
drug blood undetect level
bind human psma sub-nanomolar affin
shown cell activ cytokin
product prolifer redirect target
dna-bas
trial week trial
investor current attribut littl valu program believ fair
amount progen upsid opportun resid within given optim
doctor spoke toward potenti psma therapeut agent advanc
prostat cancer set shown support multipl billion dollar product
similar moa xtandi zytiga recent launch erleada blockbust project
consensu therapeut differ util radionuclid remain
fulli elucid challeng make definit call compound
produc best clinic profil despit second possibl third -to-market
mover believ prostat cancer market larg enough sustain multipl player
given data date small iit interpret
result caution studi believ progen need establish
produc competit respons rate repeat dose
contribut intoler ae profil dose strategi help placat
potenti issu pend clinic data adopt conserv stanc
asset assign po us/eu peak sale
price compar xofigo bayer radiotherapeut
indic mcrpc pt bone metastas analog
market penetr assum may
reserv therapi least initi face potenti uphil battl
compet novartis/endocyt three
four-year lead market provid registr trial design similar
prior chemo believ trial could support gradual uptak
set long-term
mcrpc patient
patient
patient
patient
relistor peripher act mu-opioid antagonist approv fda
treatment opioid-induc constip oic drug market
bausch health progen elig tier royalti net sale
mileston payment relistor gener consensu believ
reach evalu pharma manag expect continu growth
express credit special field forc bausch health enlist drive
estim relistor royalti stream could worth reflect
relistor sale time patent expir
progen tier royalti subject non-recours securit loan healthcar
royalti partner term loan progen receiv up-front
earli progen paid interest loan annual rate start march
royalti revenu receiv excess loan interest incur use
pay princip balanc remain princip balanc must paid full
loan matur june
arriv target price use blend valuat approach includ
product-bas dcf dcf
dcf model assum discount rate account earli commerci
stage compani fulli dilut share million long-term oper margin
tax rate assign per share pipelin valu account
basket trial would expand azedra label tumor indic detail
dcf compon includ follow
 a-bas valuat scenario support target reflect
reduct reduct sg increas revenu
assign weight dcf think progen prospect
acquisit target longer term natur primarili base
upsid case develop prostat cancer agent
probabl success
standard probabl success assumpt phase asset
phase asset phase asset asset nda/bla stage
slight adjust base histor probabl success specif diseas
categori standard mind assign follow probabl success
pyl slightli standard po asset reflect
standard po asset enter clinic studi
reflect small sampl size iit clinic studi
equival
compani cash cash equival end septemb
project net cash use oper
blue sky scenario reflect success launch pyl posit data
would support registr trial scenario would increas
 likelihood given increas attract asset weight increas
grey sky scenario assum failur prostat cancer clinic trial
modest penetr azedra pheo/para addit valu assign azedra
regulatory/clin risk includ limit trial enrol delay poorli
design studi
inadequ endpoint enough power neg
safety/efficaci signal neg dsmb/health author rule specif
emerg safeti issu azedra lack efficacy/safeti issu
studi
develop risk associ pyl compound approv base
compound new primari endpoint
liquidity/fund difficulti develop candid
manufacturing/suppli risk includ limit suppli disrupt product
batch adher
contamin technic difficulti produc function complex molecul delay
construction/certif new facil inadequ lack materi
qualiti standard manufactur shutdown due
manufactur radiotherapeut demand azedra meet
pyl fluorine-label asset requir use cyclotron activ
radionuclid limit number activ cyclotron us
commerci risk includ limit lower expect adopt drug
target popul competit clinical/exist agent payer-impos access
access reimburs issu azedra futur commerci product
competit pressur lutathera could attract product profil
azedra lower price point pyl may face competit
diagnost use may three-four year behind first
psma-target therapeut market
price challeng given pyl expens convent imag
may compet multipl psma-target agent
research develop expens
sell gener administr expens
profit loss tax
weight average share use calcul dilut ep
charl martineau pm univers toronto figur balanc sheet
cash equival
prepaid expens current asset
properti equip net
commit conting
chang asset liabil
prepaid expens asset
net cash use oper activ
purchas properti equip
sale ppe
purchas invest
sale/matur invest
net cash use invest activ
proce note payabl
proce issuanc debt
proce exercis stock option
payment offer cost
payment debt issuanc cost
proce issuanc prefer stock net issuanc cost
proce issuanc common stock net
net cash use financ activ
net decreas increas cash cash equival
cash equival begin period
cash equival end period
compani mention price
